[go: up one dir, main page]

PL1643983T3 - Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy - Google Patents

Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy

Info

Publication number
PL1643983T3
PL1643983T3 PL04776717T PL04776717T PL1643983T3 PL 1643983 T3 PL1643983 T3 PL 1643983T3 PL 04776717 T PL04776717 T PL 04776717T PL 04776717 T PL04776717 T PL 04776717T PL 1643983 T3 PL1643983 T3 PL 1643983T3
Authority
PL
Poland
Prior art keywords
sphingosine
methods
vascular endothelial
vascular permeability
apoptosis
Prior art date
Application number
PL04776717T
Other languages
English (en)
Inventor
Timothy Hla
Teresa Sanchez
Ji-Hye Paik
Kevin P Claffey
Original Assignee
Univ Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut filed Critical Univ Connecticut
Publication of PL1643983T3 publication Critical patent/PL1643983T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04776717T 2003-06-24 2004-06-18 Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy PL1643983T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48223403P 2003-06-24 2003-06-24
PCT/US2004/019420 WO2005002559A2 (en) 2003-06-24 2004-06-18 Methods of inhibiting vascular permeability and apoptosis
EP04776717A EP1643983B1 (en) 2003-06-24 2004-06-18 Methods of inhibiting vascular permeability and apoptosis

Publications (1)

Publication Number Publication Date
PL1643983T3 true PL1643983T3 (pl) 2010-10-29

Family

ID=33563841

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04776717T PL1643983T3 (pl) 2003-06-24 2004-06-18 Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy

Country Status (14)

Country Link
US (3) US7838562B2 (pl)
EP (1) EP1643983B1 (pl)
JP (2) JP2007523858A (pl)
CN (2) CN100431534C (pl)
AT (1) ATE466572T1 (pl)
AU (1) AU2004253473B2 (pl)
BR (1) BRPI0411831A (pl)
CA (3) CA2778309C (pl)
DE (1) DE602004027045D1 (pl)
ES (1) ES2342396T3 (pl)
MX (1) MXPA05014216A (pl)
PL (1) PL1643983T3 (pl)
PT (1) PT1643983E (pl)
WO (1) WO2005002559A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094965A2 (en) 2002-05-08 2003-11-20 Neuronova Ab Modulation of neural stem cells with s1p or lpa receptor agonists
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
CA2595469A1 (en) * 2005-01-21 2006-07-27 Pu Xia A method of treating cellular damage
KR100773765B1 (ko) 2005-11-24 2007-11-12 재단법인서울대학교산학협력재단 개선된 스핑고신 유사체의 제조 방법
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
KR101686369B1 (ko) * 2006-09-26 2016-12-13 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
RS55585B1 (sr) 2006-11-22 2017-06-30 Clinical Research Associates LLC Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma
CA2925175A1 (en) 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
CN102464590B (zh) * 2010-11-18 2013-10-23 中国科学院上海药物研究所 一类免疫调节剂及其制备方法和用途
ES2388273B1 (es) * 2011-03-16 2013-10-01 Consejo Superior De Investigaciones Científicas (Csic) Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada
WO2013148460A1 (en) 2012-03-26 2013-10-03 Swenson Rolf E Novel sphingosine 1-phosphate receptor antagonists
US9220706B2 (en) * 2012-06-01 2015-12-29 National Institutes Of Health (Nih) Inhibition of leukemic stem cells by PP2A activating agents
EP2895184A4 (en) * 2012-09-12 2016-09-07 Oklahoma Med Res Found MODULATION OF A PODOPLANIN-MEDIATED BLOOD PLATE ACTIVATION
WO2014175287A1 (ja) * 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
WO2016035769A1 (ja) * 2014-09-01 2016-03-10 パスロジ株式会社 ユーザ認証方法及びこれを実現するためのシステム
WO2016115092A1 (en) * 2015-01-12 2016-07-21 La Jolla Institute For Allergy And Immunology Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
US10111841B2 (en) 2015-06-19 2018-10-30 University Of South Florida Stabilization of alcohol intoxication-induced cardiovascular instability
CN105395530A (zh) * 2015-11-27 2016-03-16 天津医科大学总医院 芬戈莫德的新用途
CN105640928A (zh) * 2016-02-26 2016-06-08 南京医科大学 Fty720在制备预防与治疗缺血性脑卒药物中的应用
CN115120724A (zh) * 2017-05-22 2022-09-30 北京蔚蓝之源医药科技有限公司 治疗再生障碍性贫血的方法和药物组合物
EP3747471A4 (en) * 2018-02-02 2021-10-27 Kyoto University MEDICINE FOR PREVENTING OR TREATING OPHTHALMIC DISEASE ASSOCIATED WITH INTRAOCULAR NEOVASCULARIZATION AND / OR INCREASED VASCULAR PERMEABILITY
EP3677259A1 (en) * 2019-01-07 2020-07-08 Mosaiques Diagnostics And Therapeutics AG Use of arachidonyl trifluoromethyl ketone
US12472171B2 (en) * 2020-08-19 2025-11-18 Biogen Ma Inc. Methods for treating hypercholesterolemia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2167805A1 (en) * 1993-07-23 1995-02-02 L. David Tomei Methods of treating apoptosis and associated conditions
US5948820A (en) 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JPH11246434A (ja) * 1998-02-25 1999-09-14 Sumitomo Pharmaceut Co Ltd ｂａｘの低下及び／又はｂｃｌ−２の増加誘導剤
WO1999046277A1 (en) * 1998-03-09 1999-09-16 Smithkline Beecham Corporation HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
KR100883184B1 (ko) * 2000-12-11 2009-02-12 암젠 인코포레이션 Ｃｘｃｒ3 길항제
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
JPWO2003014727A1 (ja) * 2001-08-08 2004-11-25 中外製薬株式会社 心疾患治療剤
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
CA2472680A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
MXPA05014216A (es) 2006-03-13
BRPI0411831A (pt) 2006-08-08
CN101518524A (zh) 2009-09-02
CN100431534C (zh) 2008-11-12
DE602004027045D1 (de) 2010-06-17
US20080039530A1 (en) 2008-02-14
CA2778309A1 (en) 2005-01-13
AU2004253473A1 (en) 2005-01-13
US7838562B2 (en) 2010-11-23
PT1643983E (pt) 2010-06-18
ATE466572T1 (de) 2010-05-15
CA2529318A1 (en) 2005-01-13
WO2005002559A3 (en) 2005-04-14
AU2004253473B2 (en) 2010-03-04
CA2529318C (en) 2013-09-17
CN1826104A (zh) 2006-08-30
CA2778126A1 (en) 2005-01-13
WO2005002559A2 (en) 2005-01-13
ES2342396T3 (es) 2010-07-06
EP1643983B1 (en) 2010-05-05
JP2014088421A (ja) 2014-05-15
EP1643983A2 (en) 2006-04-12
US20110015159A1 (en) 2011-01-20
US9101575B2 (en) 2015-08-11
JP2007523858A (ja) 2007-08-23
CA2778309C (en) 2014-12-02
US20150283154A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
PL1643983T3 (pl) Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy
UA98629C2 (ru) Соединения и способ модуляции киназ
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
MX2007012237A (es) Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos.
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
MX2009006688A (es) Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
MXPA05012678A (es) Forma cristalina del agonista del receptor adrenergico beta2.
TW200626068A (en) Active compounds for seed treatment
WO2007109251A3 (en) Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
WO2008060907A3 (en) Pyrrolo-pyridine kinase inhibitors
WO2005086860A3 (en) Methods for generating insulin-producing cells
WO2008028141A3 (en) Raf inhibitor compounds and methods of use thereof
MX2009007023A (es) Agonistas de receptores heterociclicos para el tratamiento de diabetes y trastornos metabolicos.
WO2009120919A3 (en) Fenofibrate dosage forms
WO2007098474A8 (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists
WO2007092190A3 (en) Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
TNSN08140A1 (pl)
WO2008057930A3 (en) Methods of treating neuropathic pain with retinoic acid receptor agonists
MX2009001062A (es) Agonistas de ep2.
WO2007100640A3 (en) Growth hormone receptor antagonist cancer treatment
WO2006073890A3 (en) Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
EP2510925A3 (en) Small-Molecule modulators of TRP-P8 activity
EA201100255A1 (ru) 5-алкинилпиримидины
WO2006007378A3 (en) Pyrrolotriazine kinase inhibitors
RU2014124430A (ru) Средство для лечения фиброза кишечника